Navigation Links
Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum
Date:2/2/2009

o 20% rate as the world medical community recognizes the benefits to maintaining healthy hormone levels throughout life. Currently, injectable GH therapy costs approximately $1000/month, and with the technological advances captured by Secretropin(R), the cost range has been significantly reduced to between $150 and $200/month.

The Millennium Health Center, Inc. participated in the development of Secretropin(R) and provides ongoing clinical research (report). As of October 2006, there are over 3000 patient months of data being compiled by a number of independent centers throughout the U.S., Australia, New Zealand, India, Russia, Thailand, China, and Dubai. So far, Secretropin's(R) ability to increase growth hormone production has been reported in excess of 95% of the cases.

The combination of known benefits of healthy levels of human growth hormone, plus Secretropin's(R) clinically documented response rate, added to its cost-effectiveness, is what is being labeled as a responsible first-step approach to pursuing age-appropriate hormonal balanced therapy.

    For additional information:

    Mark L. Gordon, M.D.
    Millennium Health Centers, Inc.
    Email: Info@secretropinrx.com

Website: http://www.secretropinrx.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Millennium Health Centers, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
2. ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments
3. DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season
4. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
5. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
6. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
7. XTENT to Retain Investment Bank to Pursue Strategic Alternatives
8. N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency
9. New uses for imidazolium salts in medicine and alternative energy
10. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
11. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... communication, computation and more powerful ways...se quantum states as carriers of information is an...ave shown, mathematically, how to gently tease out...eping the information intact. Their work is report...s and highlighted with a Viewpoint in Physics (...
(Date:11/23/2009)...wswire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: ...er27,2009astheex-dividenddateforits$200millionspec...ationtransactioncompletedonNovember2,2009.Thedivid...ecordontherecorddate,December1,2009.NASDAQhassetth...hareofcommonstockforpurposesoftheex-dividenddateon...
(Date:11/23/2009)...-FirstCall/--NeogenCorporation(Nasdaq: NEOG )annou...ogen,sBoardofDirectorsatthecompany,srecentannualme...rsofexperienceinthefood,agriculture,andtradeindust...lturaleconomicsatVirginiaTechUniversity.FromJanuar...ulturenegotiatorwiththerankofambassador. ,, "Si...
(Date:11/23/2009)...uneDesignC or p.(IDC)announcedtodaythatDr.BruceL.A...sasuccessfultrackrec or dinbiotechnologyexecutivem...ymoGenetics,inSeattle,WAandChiefScientificOfficera...ttp://www.newscom.com/cgi-bin/prnh/20091123/SF1522...iveOfficercommented,"IamdelightedtowelcomeDr.Bruce...
Breaking Biology Technology:PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Richard T. Crowder Joins Neogen's Board of Directors 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2
...ocus on Late-Stage and Marketed ...nd OXFORD, England, May 1 ,EUSA Pharma Inc (,EUSA,...y,focused on oncology, pain control and critical c...clonal antibody research business to the French,co...rently, EUSA has,divested its recombinant L-aspara...
...sdaq:,VICL) today announced that the company will ...ch 31, 2008, before the opening of trading on,Thur...cast to discuss the,financial results and provide ... May 8. The call is open on a listen-only basis to...details on independent and partnered,development p...
...:,FVRL), a biopharmaceutical company developing pa...atment of cancer, announced today that it will,hos...Eastern Time on,Thursday, May 8, 2008 to discuss t... A press release will be issued after the U.S. sto...wscom.com/cgi-bin/prnh/20080404/LAF521LOGO ), A l...
Other Biology Technology:EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 2EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 3Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results 2Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008 2
(Date:11/24/2009)...ON ROUGE Antarctica has long held secrets of the ...l recently, there has been very little information... miles of ice for millions of years. Now, a team o...U have been funded to the tune of $10 million dol...o get to the bottom of things literally. These sc...
(Date:11/23/2009)...ngton, D.C. The community-associated strain of th...a resistant to most common antibioticsposes a far ... making its way into hospitals, according to a stu...iseases . , The new threat is easily picked up ...es and has increased the overall burden of MRSA wi...
(Date:11/23/2009)...ngton, CT Current research suggests that a common... The related report by Nichols et al, "Unique Lip...Class of TLR2 Ligands Capable of Enhancing Autoimm... American Journal of Pathology . , Multiple scle...cks the brain and spinal cord, affects nearly 1 in...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Cambrex Continuous Flow Microwave Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award 5599 1Cambrex Continuous Flow Microwave Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award 5599 2Babies Injured in Car Seats Used Outside of Cars 59817 1Babies Injured in Car Seats Used Outside of Cars 59817 2Babies Injured in Car Seats Used Outside of Cars 59817 3School Meals Need to Get Healthier 3A Report 59815 1School Meals Need to Get Healthier 3A Report 59815 2School Meals Need to Get Healthier 3A Report 59815 3School Meals Need to Get Healthier 3A Report 59815 4
...nced the winners of its student travel award to at...and the International Biophysics Congress in Long ...nts of this competitive award are selected based o...ho will present a paper at the conference. Each a...zed at a reception on Saturday, February 2, 2008. ...
...diopathic pulmonary fibrosis is a disease with unk...cted, it is already in an advanced stage. Patients...ulmonary gas exchange, and have a very reduced qua...tment, they rarely survive 5 years after being dia...ut of 100,000 men and 7 out of 100,000 women, norm...
...unds could make sutures a relic of medical history...laced on a surgical wound and exposed to an infrar... it and the tissue, thus perfectly sealing the wou... is extracted from crab shells and has Food and Dr...t results indicate that it has strongest potential...
Other Biology News:Biophysical Society announces winners of 2008 Student Travel Awards 2Biophysical Society announces winners of 2008 Student Travel Awards 3Biophysical Society announces winners of 2008 Student Travel Awards 4Biophysical Society announces winners of 2008 Student Travel Awards 5Translational research patented first experimental treatment against idiopathic pulmonary fibrosis 2Surgery without stitches 2
Rat Anti-Mouse Endoglin Monoclonal Antibody, Fluorescein Conjugated, Clone 209701 from R&D Systems
Goat Anti-Rat CNTF R alpha Polyclonal Antibody, Unconjugated from R&D Systems
Rat Anti-Human MFRP Monoclonal Antibody, Unconjugated, Clone 291218 from R&D Systems
Goat Anti-Human RELT / TNFRSF19L Polyclonal Antibody, Unconjugated from R&D Systems
Biology Products: